NeuroOne Medical Technologies (NASDAQ: NMTC) details FY 2025 results release

Rhea-AI Filing Summary

NeuroOne Medical Technologies Corporation filed a current report stating that on December 17, 2025 it issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2025.

The press release is furnished as Exhibit 99.1 and, along with Item 2.02, is treated as furnished rather than filed under the Exchange Act, which affects how it is incorporated into other Securities Act and Exchange Act filings. The company’s common stock trades on the Nasdaq Stock Market under the symbol NMTC.

false 0001500198 0001500198 2025-12-17 2025-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 17, 2025

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-40439		27-0863354
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On December 17, 2025, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated December 17, 2025
104		Cover Page Interactive Data File (embedded with Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated:  December 17, 2025
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

2

FAQ

What did NeuroOne Medical Technologies (NMTC) disclose in this SEC report?

The report states that NeuroOne Medical Technologies Corporation issued a press release on December 17, 2025 announcing its financial results for the fiscal quarter and year ended September 30, 2025, and that this press release is attached as Exhibit 99.1.

For which period did NMTC report financial results in the December 17, 2025 release?

The company’s press release covers its fiscal quarter and year ended September 30, 2025, providing results for both the final quarter and the full fiscal year.

Where can investors find the detailed numbers from NMTC’s latest results?

Detailed financial information is contained in the company’s press release dated December 17, 2025, which is furnished as Exhibit 99.1 to the current report.

How is the NMTC earnings press release treated under SEC rules?

The information in Item 2.02, including Exhibit 99.1, is furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings.

On which exchange is NeuroOne Medical Technologies (NMTC) listed?

NeuroOne Medical Technologies Corporation’s common stock, par value $0.001 per share, is listed on The Nasdaq Stock Market LLC under the ticker symbol NMTC.

Who signed this current report for NeuroOne Medical Technologies?

The report was signed on behalf of NeuroOne Medical Technologies Corporation by David Rosa, who is identified as the company’s Chief Executive Officer, dated December 17, 2025.